Applied Therapeutics Statistics
Share Statistics
Applied Therapeutics has 116.36M shares outstanding. The number of shares has increased by 9.89% in one year.
| Shares Outstanding | 116.36M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.31% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 86.61M |
| Failed to Deliver (FTD) Shares | 6.51K |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 18.15M, so 15.6% of the outstanding shares have been sold short.
| Short Interest | 18.15M |
| Short % of Shares Out | 15.6% |
| Short % of Float | 20.96% |
| Short Ratio (days to cover) | 1.85 |
Valuation Ratios
The PE ratio is -2.36 and the forward PE ratio is -21.52.
| PE Ratio | -2.36 |
| Forward PE | -21.52 |
| PS Ratio | 28.24 |
| Forward PS | 0.8 |
| PB Ratio | -16.46 |
| P/FCF Ratio | -5.12 |
| PEG Ratio | n/a |
Enterprise Valuation
Applied Therapeutics Inc. has an Enterprise Value (EV) of 233.55M.
| EV / Earnings | -1.95 |
| EV / Sales | 23.37 |
| EV / EBITDA | -3.62 |
| EV / EBIT | -3.62 |
| EV / FCF | -4.23 |
Financial Position
The company has a current ratio of 0.76, with a Debt / Equity ratio of -0.02.
| Current Ratio | 0.76 |
| Quick Ratio | 0.76 |
| Debt / Equity | -0.02 |
| Total Debt / Capitalization | -1.84 |
| Cash Flow / Debt | -177.98 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 6.98% and return on capital (ROIC) is 394.25%.
| Return on Equity (ROE) | 6.98% |
| Return on Assets (ROA) | -2.18% |
| Return on Capital (ROIC) | 394.25% |
| Revenue Per Employee | 270.08K |
| Profits Per Employee | -3.24M |
| Employee Count | 37 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -58.22% in the last 52 weeks. The beta is 2.02, so Applied Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.02 |
| 52-Week Price Change | -58.22% |
| 50-Day Moving Average | 5.35 |
| 200-Day Moving Average | 5.63 |
| Relative Strength Index (RSI) | 20.84 |
| Average Volume (20 Days) | 5.45M |
Income Statement
In the last 12 months, Applied Therapeutics had revenue of 9.99M and earned -119.76M in profits. Earnings per share was -1.42.
| Revenue | 9.99M |
| Gross Profit | 9.64M |
| Operating Income | -64.53M |
| Net Income | -119.76M |
| EBITDA | -64.53M |
| EBIT | -64.53M |
| Earnings Per Share (EPS) | -1.42 |
Balance Sheet
The company has 49.90M in cash and 777.00K in debt, giving a net cash position of 49.12M.
| Cash & Cash Equivalents | 49.90M |
| Total Debt | 777.00K |
| Net Cash | 49.12M |
| Retained Earnings | -468.59M |
| Total Assets | 106.57M |
| Working Capital | 5.64M |
Cash Flow
In the last 12 months, operating cash flow was -55.17M and capital expenditures 0, giving a free cash flow of -55.17M.
| Operating Cash Flow | -55.17M |
| Capital Expenditures | 0 |
| Free Cash Flow | -55.17M |
| FCF Per Share | -0.65 |
Margins
Gross margin is 9.65K%, with operating and profit margins of -64.58K% and -119.85K%.
| Gross Margin | 9.65K% |
| Operating Margin | -64.58K% |
| Pretax Margin | -119.85K% |
| Profit Margin | -119.85K% |
| EBITDA Margin | -645.79% |
| EBIT Margin | -645.8% |
| FCF Margin | -552.12% |
Dividends & Yields
APLT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -151.06% |
| FCF Yield | -50.35% |
Analyst Forecast
The average price target for APLT is $5, which is 431.9% higher than the current price. The consensus rating is "Hold".
| Price Target | $5 |
| Price Target Difference | 431.9% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -10.34 |
| Piotroski F-Score | 5 |